Publications by authors named "Jo Woodward"
Article Synopsis
- The study compared the pharmacokinetics (PK) and systemic effects of fluticasone/formoterol delivered via a breath-actuated inhaler (BAI) versus a pressurized metered-dose inhaler (pMDI) in healthy volunteers.
- Study 1 focused on assessing drug exposure by administering single doses of fluticasone/formoterol through different devices, aiming to confirm that the BAI delivers a similar or better concentration of the drug compared to the pMDI.
- Study 2 involved evaluating the systemic pharmacodynamic (PD) effects of formoterol, specifically monitoring serum potassium levels after administration, confirming the safety and effectiveness of BAI in comparison to pMDI methods.
Introduction: A combination of fluticasone propionate/formoterol fumarate (FP/FORM) has been incorporated within a novel, breath-triggered device, named K-haler. This low resistance device requires a gentle inspiratory effort to actuate it, triggering at an inspiratory flow rate of approximately 30 L/min; thus avoiding the need for coordination of inhalation with manual canister depression. The aim of the study was to evaluate total and regional pulmonary deposition of FP/FORM when administered via the K-haler device.
View Article and Find Full Text PDFBackground And Aims: Take-home naloxone can prevent death from heroin/opioid overdose, but pre-provision is difficult because naloxone is usually given by injection. Non-injectable alternatives, including naloxone nasal sprays, are currently being developed. To be effective, the intranasal (i.
View Article and Find Full Text PDFLow absolute bioavailability of oral naloxone in healthy subjects.
Int J Clin Pharmacol Ther
May 2012
Objective: To determine the absolute bioavailability of naloxone from oral doses ranging from 5 mg to 120 mg.
Materials And Methods: In this open-label study, 28 healthy subjects received naloxone 1 mg (0.4 mg/ml) as an intravenous infusion (reference treatment), and the following oral doses as prolonged release (PR) naloxone tablets: 5 mg, 20 mg, 40 mg, 80 mg and 120 mg.
Objectives: This exploratory study in healthy volunteers investigated the effect of single doses of oxycodone on gastrointestinal (GI) transit time and the degree to which a single dose of naloxone reverses the oxycodone-induced effect.
Methods: Fifteen healthy male volunteers received: oxycodone 10 and2 0 mg, oxycodone/naloxone 10/5 and 20/10 mg (all as prolonged release tablets) and placebo. Each dose was radiolabelled and administered with a capsule containing radiolabelled resin (surrogate for GI contents).